Cretostimogene for High-Risk NMIBC: CORE-008, BOND-003, and PIVOT-006
By Sia Daneshmand, MD - Last Updated: February 20, 2025At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Sia Daneshmand, MD, of University of Southern California, provides overviews and updates from three clinical trials involving cretostimogene for High-Risk NMIBC: CORE-008, BOND-003, and PIVOT-006.
Advertisement
Advertisement
Related Posts
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.